Klaus Mross

Summary

Affiliation: University of Freiburg
Country: Germany

Publications

  1. ncbi Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
    K Mross
    Tumour Biology Center at the Albert Ludwigs University, Freiburg, Germany
    Eur J Cancer 43:55-63. 2007
  2. ncbi Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)
    Klaus Mross
    Tumor Biology Center Albert Ludwigs University, Freiburg, Germany
    Anticancer Drugs 15:15-22. 2004
  3. ncbi Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
    Klaus Mross
    Tumor Biology Center, Albert Ludwigs University Freiburg, 79106, Freiburg im Breisgau, Germany
    Cancer Chemother Pharmacol 54:514-24. 2004
  4. ncbi Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors
    K Mross
    Tumor Biology Center, Albert-Ludwigs-University Freiburg, Germany
    Int J Clin Pharmacol Ther 41:618-9. 2003
  5. ncbi Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours
    Klaus Mross
    Tumour Biology Center at the Albert Ludwigs University Freiburg, Breisacher Strasse 117, D 79106 Freiburg i Br, Germany
    Eur J Cancer 41:1291-9. 2005
  6. ncbi [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]
    Klaus Mross
    , Breisacherstrasse 117, D-79106 Freiburg iBr
    Pharm Unserer Zeit 37:404-15. 2008
  7. ncbi Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Breisacherstrasse 117, D 79106, Freiburg, Germany
    J Clin Oncol 26:5511-7. 2008
  8. ncbi Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial
    K Mross
    Department of Medical Oncology, Tumor Biology Center, Albert Ludwigs University Freiburg, Germany
    Onkologie 25:503-8. 2002
  9. ncbi Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications
    K Mross
    Tumor Biology Center, Albert Ludwigs University Freiburg, Germany
    Int J Clin Pharmacol Ther 43:601-2. 2005
  10. ncbi PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing
    Klaus Mross
    Department of Medical Oncology, Tumor Biology Center at the Albert Ludwigs University, Germany
    Onkologie 29:444-50. 2006

Detail Information

Publications42

  1. ncbi Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
    K Mross
    Tumour Biology Center at the Albert Ludwigs University, Freiburg, Germany
    Eur J Cancer 43:55-63. 2007
    ....
  2. ncbi Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)
    Klaus Mross
    Tumor Biology Center Albert Ludwigs University, Freiburg, Germany
    Anticancer Drugs 15:15-22. 2004
    ..This trial showed that BBR 3576 has a manageable toxicity profile on a 4-week schedule. Phase II studies have started in patients with solid tumors, as suggested by preclinical data in different in vivo model systems...
  3. ncbi Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
    Klaus Mross
    Tumor Biology Center, Albert Ludwigs University Freiburg, 79106, Freiburg im Breisgau, Germany
    Cancer Chemother Pharmacol 54:514-24. 2004
    ..We conducted an open-label phase I study to determine the pharmacokinetic profile of a single dose of liposome-encapsulated doxorubicin (Myocet) in patients with various solid tumors. Safety and tolerability were monitored...
  4. ncbi Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors
    K Mross
    Tumor Biology Center, Albert-Ludwigs-University Freiburg, Germany
    Int J Clin Pharmacol Ther 41:618-9. 2003
  5. ncbi Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours
    Klaus Mross
    Tumour Biology Center at the Albert Ludwigs University Freiburg, Breisacher Strasse 117, D 79106 Freiburg i Br, Germany
    Eur J Cancer 41:1291-9. 2005
    ..The minimum biologically active dose was established at 750 mg/day whereas the recommended dose for phase III studies is 1200 mg/day...
  6. ncbi [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]
    Klaus Mross
    , Breisacherstrasse 117, D-79106 Freiburg iBr
    Pharm Unserer Zeit 37:404-15. 2008
  7. ncbi Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Breisacherstrasse 117, D 79106, Freiburg, Germany
    J Clin Oncol 26:5511-7. 2008
    ..The aim of this trial was to identify the maximum tolerated dose (MTD) of BI 2536 and to determine the safety, pharmacokinetics, and antitumor activity in patients who had advanced solid tumors...
  8. ncbi Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial
    K Mross
    Department of Medical Oncology, Tumor Biology Center, Albert Ludwigs University Freiburg, Germany
    Onkologie 25:503-8. 2002
    ..Aim of this study was to characterize the difference in pharmacokinetics (PK) of paclitaxel (PAC) after 1-h and 3-h infusion in humans and to define a pharmacodynamic relationship between PAC PK and myelotoxicity...
  9. ncbi Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications
    K Mross
    Tumor Biology Center, Albert Ludwigs University Freiburg, Germany
    Int J Clin Pharmacol Ther 43:601-2. 2005
  10. ncbi PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing
    Klaus Mross
    Department of Medical Oncology, Tumor Biology Center at the Albert Ludwigs University, Germany
    Onkologie 29:444-50. 2006
    ....
  11. ncbi Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors
    Klaus Mross
    Tumour Biology Center and Department of Radiology, Section MR Development, Albert Ludwigs Universitat Freiburg, Freiburg, Germany
    Clin Cancer Res 16:311-9. 2010
    ..Dynamic contrast-enhanced magnetic resonance imaging assessed antiangiogenic effect in 42 patients...
  12. ncbi [Clinical trials: prerequisite of evidence-based oncology: reality, perspectives and a new tool recruited--the Internet]
    K Mross
    Klinik für Tumorbiologie an der Albert Ludwigs Universität, Freiburg i Br
    Onkologie 24:24-34. 2001
    ..This will be more than an incremental step forward to deliver the best possible clinical care towards the ultimate goal: to deliver evidence-based medicine en route to a cure for more cancer patients than ever...
  13. ncbi [Chemotherapy of colonic carcinoma in the year 2001]
    K Mross
    Klinik fur Tumorbiologie, Albert Ludwig Universität Freiburg
    Praxis (Bern 1994) 90:497-510. 2001
    ..The median survival of patients with metastatic colon cancer is between 12 and 18 month. It will be discussed in which way this range depends on the chemotherapeutical strategy...
  14. ncbi Clinical trials with anti-angiogenic agents in hematological malignancies
    Michael Medinger
    Department of Medical Oncology, Tumor Biology Center at the Albert Ludwigs University, Breisacherstrasse 117, D 79106 Freiburg, Germany
    J Angiogenes Res 2:10. 2010
    ..This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis...
  15. ncbi The pharmacokinetics of a 1-h paclitaxel infusion
    K Mross
    Department of Medical Oncology and Clinical Pharmacology, Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany
    Cancer Chemother Pharmacol 45:463-70. 2000
    ..To characterize the disposition of paclitaxel (PAC) after a 1-h infusion in humans and define if possible a pharmacodynamic relationship between PAC disposition and the observed toxicity...
  16. ncbi Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
    Klaus Mross
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany
    Vasc Cell 3:16. 2011
    ..abstract:..
  17. ncbi Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study
    Simone Steinbild
    Tumor Biology Center at the Albert Ludwigs University Freiburg and MR Development and Application Center of the University Hospital, Freiburg, Germany
    Onkologie 30:629-35. 2007
    ..Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to monitor antiangiogenic effects...
  18. ncbi A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer
    Joachim Drevs
    Tumor Biology Center, Albert Ludwigs University Freiburg, Breisacherstrasse 117, 79106 Freiburg, Germany
    Anticancer Res 30:2335-9. 2010
    ..PTK787/ZK 222584 (PTK/ZK) offers a novel approach to inhibit tumour angiogenesis...
  19. ncbi Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen
    Stephan Mielke
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg i Br, Germany
    Anticancer Res 25:4423-7. 2005
    ..Paclitaxel pharmacokinetics were shown to be related to toxicity and survival. Patients and..
  20. ncbi Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin
    Clemens Unger
    Department Medical Oncology, Tumor Biology Center, Freiburg, Germany
    Clin Cancer Res 13:4858-66. 2007
    ..The purpose of the phase I study was to characterize the toxicity profile of DOXO-EMCH, establish a recommended dose for phase II studies, and assess potential anticancer activity...
  21. ncbi Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
    Joachim Drevs
    Tumor Biology Center, MR Development and Application Center, Albert Ludwigs University, Freiburg, Germany
    J Clin Oncol 25:3045-54. 2007
    ..This phase I study was designed to evaluate the safety and tolerability of increasing doses of AZD2171, with additional assessments of pharmacokinetics, pharmacodynamics, and efficacy...
  22. ncbi First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours
    Clemens Unger
    Klinik für Tumorbiologie an der Albert Ludwigs Universität, Freiburg, Germany
    Eur J Cancer 46:920-5. 2010
    ..To identify the maximum-tolerated dose (MTD) and pharmacokinetics of oral perifosine...
  23. ncbi Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2
    Marc Azemar
    Tumor Biology Center, Freiburg, Germany
    Breast Cancer Res Treat 82:155-64. 2003
    ..No hematologic, renal, and/or cardiovascular toxicities were noted. Our results demonstrate that local therapy with scFv(FRP5)-ETA can be effective against ErbB2 expressing tumors justifying further clinical development of this reagent...
  24. ncbi Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer
    Stephan Mielke
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Clin Cancer Res 11:4843-50. 2005
    ..05 micromol/L (T >0.05) remains almost constant. As both Cremophor EL and paclitaxel are neurotoxic, we evaluated their pharmacodynamic effects on the development of peripheral neuropathy as the most important nonhematologic toxicity...
  25. ncbi Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer
    Simone Steinbild
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Freiburg, Germany
    Onkologie 32:488-92. 2009
    ..Bendamustine is a drug with a favorable side effect spectrum and it offers a chance to overcome tumor resistance in pretreated patients with metastatic breast cancer (MBC)...
  26. ncbi Treatment of anthracycline extravasation with dexrazoxane -- clinical experience
    Annette Frost
    Tumor Biology Center at the Albert Ludwigs University, Freiburg i.Br, Germany
    Onkologie 29:314-8. 2006
    ..RESULTS: The 2 patients treated with dexrazoxane recovered completely without any sequelae. CONCLUSIONS: Treatment of antracycline extravasation with dexrazoxane is potentially useful and safe...
  27. ncbi Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes
    Stephan Mielke
    Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg i Br, Germany
    Eur J Cancer 42:24-30. 2006
    ..In this report we review and discuss the pathogenesis, incidence, risk factors, diagnosis, pharmacodynamics and treatment options for PAC-induced PNP...
  28. ncbi Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer
    Stefan Fuxius
    Tumor Biology Center, Albert Ludwigs University Freiburg, 79106 Freiburg i Br, Germany
    Anticancer Drugs 13:899-905. 2002
    ..The results, particularly those in metastatic renal carcinoma, are encouraging and worthy of further evaluation in phase II trials...
  29. ncbi Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer
    B Hauns
    Department of Medical Oncology, Tumor Biology Center at the Albert-Ludwigs-University Freiburg, Breisacher Str. 117, D-79106 Freiburg i. Br, Germany
    Phytother Res 15:34-8. 2001
    ..Since an improvement was observed in some patients despite the failure of the conventional 5-FU pretreatment, it would be interesting to evaluate whether the application of 5-FU plus GBE 761 ONC as a first line treatment is of benefit...
  30. ncbi c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis
    Michael Medinger
    Tumor Biology Center, Albert Ludwigs University Freiburg, Freiburg im Breisgau, Germany
    Pathol Oncol Res 16:295-301. 2010
    ..Expression of c-kit was found in tumor samples with varying intensities and infrequently...
  31. ncbi Clinical phase I study with one-hour paclitaxel infusion
    K Mross
    Department of Medical Oncology and Clinical Pharmacology, Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany
    Ann Oncol 9:569-72. 1998
    ..We evaluated a one-hour infusion schedule within a phase I study to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD), and the anti-cancer efficacy...
  32. ncbi Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
    J Drevs
    Tumor Biology Center, Freiburg, Germany
    Ann Oncol 16:558-65. 2005
    ....
  33. ncbi A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors
    K Mross
    Department of Medical Oncology, Tumor Biology Center at the University of Freiburg, Berlin, Germany
    Ann Oncol 15:1284-94. 2004
    ..However, because of the superior safety profile, we recommend the 3-day schedule for BAY 38-3441 at a dose of 320 mg/m2/day as 30-min infusions for further phase II studies...
  34. ncbi A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
    S Steinbild
    Tumor Biology Center, Albert Ludwigs University Freiburg Freiburg, Germany
    Br J Cancer 97:1480-5. 2007
    ..Sorafenib has antitumour activity in HRPCP when evaluated for RECIST- and PSA-based response. Further investigation as a component of combination regimens is necessary to evaluate its definite or overall clinical benefit for HRPCP...
  35. ncbi DCE-MRI in clinical trials: data acquisition techniques and analysis methods
    R Strecker
    University Hospital, Albert Ludwigs University, Freiburg, Germany
    Int J Clin Pharmacol Ther 41:603-5. 2003
  36. ncbi Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma--what is a useful tool in clinical studies of anti-angiogenic drugs?
    K Mross
    Tumor Biology Center at the Albert Ludwigs University Freiburg, Germany
    Int J Clin Pharmacol Ther 40:573-4. 2002
  37. ncbi Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions
    Hans Gelderblom
    Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 20:574-81. 2002
    ....
  38. ncbi Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liv
    Bruno Morgan
    University of Leicester, United Kingdom
    J Clin Oncol 21:3955-64. 2003
    ....
  39. ncbi Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h
    Stephan Mielke
    Department of Hematology and Oncology, University of Freiburg Medical Center, Germany
    Anticancer Drugs 14:785-92. 2003
    ..A majority of patients experiencing neurotoxic effects require the investigation of potential nerve protectors in future clinical trials accompanying PAC therapy...
  40. ncbi Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Stephen Chan
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Rd, Nottingham N65 1PB, United Kingdom
    J Clin Oncol 23:5314-22. 2005
    ....
  41. ncbi Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
    Anja Henningsson
    Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 11:8097-104. 2005
    ..To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol)...
  42. ncbi Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
    Tristan M Sissung
    Clinical Pharmacology Research Core, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA
    Eur J Cancer 42:2893-6. 2006
    ..This pilot study suggests that paclitaxel-induced neuropathy and neutropenia might be linked to inherited variants of ABCB1 through a mechanism that is unrelated to altered plasma pharmacokinetics...